SAV

SAV(SAV)股票分析

$24.750

+0.020 (+0.08%)收盤時

Loading chart…
最高
24.800
開盤
24.800
成交量加權均價
24.75
成交量
1.58K
市值
—
最低
24.688
成交金額
39.17K
企業價值/稅息折舊攤銷前利潤(TTM)
—

AI 分析 of SAV (SAV)

買進

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

SAV 常見問題 —— 由 Alphio AI 解答

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易